Global Multiple Myeloma Drugs Market 2017-2021

Global Multiple Myeloma Drugs Market 2017-2021

  • December 2016 •
  • 86 pages •
  • Report ID: 4594272 •
  • Format: PDF
About Multiple Myeloma Drugs
Multiple myeloma is an abnormal growth and accumulation of plasma cells in the bone marrow leading to malignancy. This can be caused by the overproduction of monoclonal immunoglobulins such as IgG, IgA, IgD, or IgE; or Bence-Jones protein. Under normal conditions, stem cells develop into B lymphocytes, mature in the lymph nodes, and are transported throughout the body. On the entry of foreign substances into the body, these B-cells develop into plasma cells and produce immunoglobulins against the disease. However, in multiple myeloma, the B-cells are damaged and give rise to many malignant plasma cells that produce excessive immunoglobulins of a single type, which the body does not require.

Technavio’s analysts forecast the global multiple myeloma drugs market to grow at a CAGR of 9.19% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global multiple myeloma drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent multiple myeloma.

The market is divided into the following segments based on geography:
- Americas

Technavio's report, Global Multiple Myeloma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Amgen
- Celgene
- Johnson & Johnson
- Novartis
- Takeda Pharmaceuticals

Other prominent vendors
- AB Science
- AbbVie
- Acceleron Pharma
- Acetylon Pharmaceuticals
- Adaptimmune Therapeutics
- Alexion Pharmaceuticals
- AmpliMed Corporation
- Array BioPharma
- Benovus Bio
- BioInvent
- Biokine Therapeutics
- Biotest
- bluebird bio
- Bristol-Meyer Squibb
- Calithera Biosciences
- CASI Pharmaceuticals
- Celldex Therapeutics
- Cellectar Biosciences
- Chroma Therapeutics
- Cleave Biosciences
- Curis
- Dicerna Pharmaceuticals
- Eureka Therapeutics
- F. Hoffmann-La Roche
- Geron Corporation
- GlycoMimetics
- GlaxoSmithKline
- ImmunoGen
- Immunomedics
- Innate Pharma
- JW Pharmaceutical
- Karyopharm Therapeutics
- Kyowa Hakko Kirin
- Merck
- Midatech Pharma
- Mirna Therapeutics
- Molecular Partners
- MorphoSys
- NOXXON Pharma
- Oncoceutics
- Oncolytics Biotech
- OncoPep
- Oncopeptides
- Ono Pharmaceutical
- Otsuka Pharmaceuticals
- Patrys
- PharmaMar
- Polyphor
- Prothena Therapeutics
- Sanofi
- Sevion Therapeutics
- Specialised Therapeutics
- Spectrum Pharmaceutical
- SymBio Pharmaceuticals
- TaiGen Biotechnology
- Tragara Pharmaceuticals
- Vaxil Therapeutics
- Vivolux

Market driver
- Growing demand for biologic therapies
- For a full, detailed list, view our report

Market challenge
- Growing popularity of complementary and alternative medicines (CAM)
- For a full, detailed list, view our report

Market trend
- Emergence of nanomedicine platform
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.

We are very sorry, but an error occurred.
Please contact if the problem remains.